When excluding the three patients that also had tissue biopsies with a luminal breast cancer subtype and PD-L1 negative status (in order to assimilate the study population of the present study even closer to the study cohort of the pivotal study IMpassion130) the median time to treatment failure was 2.83 months (IQR 2.69; 3.76) compared to 2.99 months (IQR 1.43; 4.98) in the second and beyond treatment line cohort (p = .536). This evidence concerns the gene CD274 and breast carcinoma.